semaglutide sparks nv – Compound Semaglutide
Description
While some GLP-1 drugs have FDA approval for treatment of Type 2 diabetes and/or obesity, doctors have found that they may also help treat other conditions
TRIUMPH-1's lower discontinuation rate (11.3% vs
About 5% stopped at the lowest dose, 8% at the mid dose, and 10% at the highest dose, compared to about 3% with placebo
377:839-848 [PubMed: 28854085] 322
GLP-1 medications require evaluation by a licensed healthcare professional and may not be appropriate for everyone
Your integrative medical team can adjust your medication dose and decide the best route for you to reach your target weight
